These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2223 related articles for article (PubMed ID: 12947210)

  • 1. Improved in-hospital outcomes in acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction) despite similar TIMI risk scores.
    Almeda FQ; Hendel RC; Nathan S; Meyer PM; Calvin JE; Klein LW
    J Invasive Cardiol; 2003 Sep; 15(9):502-6. PubMed ID: 12947210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
    Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
    Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.
    Morrow DA; Antman EM; Snapinn SM; McCabe CH; Theroux P; Braunwald E
    Eur Heart J; 2002 Feb; 23(3):223-9. PubMed ID: 11792137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
    Okmen E; Cakmak M; Tartan Z; Cam N
    Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial.
    Cantor WJ; Goodman SG; Cannon CP; Murphy SA; Charlesworth A; Braunwauld E; Langer A
    Am Heart J; 2005 Feb; 149(2):275-83. PubMed ID: 15846265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A risk score to predict bleeding in patients with acute coronary syndromes.
    Mehran R; Pocock SJ; Nikolsky E; Clayton T; Dangas GD; Kirtane AJ; Parise H; Fahy M; Manoukian SV; Feit F; Ohman ME; Witzenbichler B; Guagliumi G; Lansky AJ; Stone GW
    J Am Coll Cardiol; 2010 Jun; 55(23):2556-66. PubMed ID: 20513595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognosis after acute coronary syndrome. Lack of difference according to the sex].
    Bounhoure JP; Farah B; Fajadet J; Marco J
    Bull Acad Natl Med; 2004; 188(3):383-97; discussion 397-9. PubMed ID: 15584651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
    Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
    Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
    Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
    N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative.
    Mehta RH; Roe MT; Chen AY; Lytle BL; Pollack CV; Brindis RG; Smith SC; Harrington RA; Fintel D; Fraulo ES; Califf RM; Gibler WB; Ohman EM; Peterson ED
    Arch Intern Med; 2006 Oct; 166(18):2027-34. PubMed ID: 17030838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials.
    Mehta RH; Greenbaum AB; Lokhnygina Y; Newby LK; Van De Werf F; Armstrong PW; Pieper KS; Califf RM; Granger CB; Harrington RA
    J Interv Cardiol; 2007 Oct; 20(5):299-306. PubMed ID: 17880325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of un-fractionated heparin and low molecular weight heparin on hospital mortality in patients with non ST elevation acute coronary syndrome (ACS).
    Angkasuwapala K; Ratanasumawong K; Ngarmukos T; Kehasukcharoen W; Boonsom W; Kamsa-ard S
    J Med Assoc Thai; 2007 Oct; 90 Suppl 1():109-14. PubMed ID: 18431893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding events with antithrombotic therapy in patients with unstable angina or non-ST-segment elevation myocardial infarction; insights from a large clinical practice registry (GRACE).
    Stiles MK; Dabbous OH; Fox KA;
    Heart Lung Circ; 2008 Feb; 17(1):5-8. PubMed ID: 17419100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New risk score for patients with acute chest pain, non-ST-segment deviation, and normal troponin concentrations: a comparison with the TIMI risk score.
    Sanchis J; Bodí V; Núñez J; Bertomeu-González V; Gómez C; Bosch MJ; Consuegra L; Bosch X; Chorro FJ; Llàcer A
    J Am Coll Cardiol; 2005 Aug; 46(3):443-9. PubMed ID: 16053956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shen J; Zhang Q; Zhang RY; Zhang JS; Hu J; Yang ZK; Zheng AF; Zhang X; Shen WF
    Coron Artery Dis; 2008 Jun; 19(4):271-7. PubMed ID: 18480672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
    Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
    Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML;
    Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy.
    Cohen M; Stinnett SS; Weatherley BD; Gurfinkel EP; Fromell GJ; Goodman SG; Fox KA; Califf RM
    Am Heart J; 2000 Jun; 139(6):962-70. PubMed ID: 10827375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
    Huynh T; Theroux P; Snapinn S; Wan Y;
    Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 112.